Guzel Mukhametshina

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Hope S. Rugo, Abhijit Barve, Cornelius F. Waller et al. · JAMA · 2016 · 145 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

Sant P. Chawla, Zsuzsanna Pápai, Guzel Mukhametshina et al. · JAMA Oncology · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacology +11